To enable the characterization of genetic heterogeneity in tumor cell populations, we developed a novel microfluidic approach that barcodes amplified genomic DNA from thousands of individual cancer cells confined to droplets. The barcodes are then used to reassemble the genetic profiles of cells from next generation sequencing data. Targeted sequencing of genes frequently mutated in AML uncovered complex clonal architecture within AML tumors that was not observable with bulk sequencing.
ABSTRACT (70 words)
To enable the characterization of genetic heterogeneity in tumor cell populations, we developed a novel microfluidic approach that barcodes amplified genomic DNA from thousands of individual cancer cells confined to droplets. The barcodes are then used to reassemble the genetic profiles of cells from next generation sequencing data. Targeted sequencing of genes frequently mutated in AML uncovered complex clonal architecture within AML tumors that was not observable with bulk sequencing.
Current tumor sequencing paradigms are inadequate to fully characterize many instances of AML (acute myeloid leukemia) 1, 2 . A major challenge has been the unambiguous identification of potentially rare and genetically heterogeneous neoplastic cell populations, with subclones capable of critically impacting tumor evolution and the acquisition of therapeutic resistance 3, 4 . Standard bulk population sequencing is often unable to identify rare alleles or definitively determine whether mutations co-occur within the same cell. Single-cell sequencing has the potential to address these key issues and transform our ability to accurately characterize clonal heterogeneity in AML.
An established approach for high-throughput single-cell sequencing uses molecular barcodes to tag the nucleic acids of individual cells confined to emulsion droplets [5] [6] [7] [8] . Although it is now feasible to perform single-cell RNA-Seq on thousands of cells using this type of approach, high-throughput single-cell DNA genotyping using droplet microfluidics has not been demonstrated on eukaryotic cells. This is primarily due to the challenges associated with efficiently lysing cells, freeing genomic DNA from chromatin and enabling efficient PCR amplification in the presence of high concentrations of crude lysate 9, 10 . To overcome these obstacles and enable the characterization of genetic diversity within cancer cell populations, we developed a novel two-step microfluidic droplet workflow that enables efficient and massively-parallel single-cell PCR-based barcoding (Fig. 1a,b) . The microfluidic workflow first encapsulates individual cells in droplets, lyses the cells and prepares the lysate for genomic DNA amplification using proteases. Following this lysate preparation step, the proteases are inactivated via heat denaturation and droplets containing the genomes of individual cells are paired with molecular barcodes and PCR amplification reagents. To demonstrate the advantage of the protease in the two-step workflow, we performed droplet-based single-cell TaqMan PCR reactions targeting the SRY locus on the Y chromosome, present as a single copy in a karyotypically normal cell (Fig. 1c) . We carried out PACS (PCR-activated cell sorting) on calcein violet stained DU145 prostate cancer cells encapsulated and lysed with or without the addition of a protease 11, 12 . In the absence of protease during cell lysis, only 5.2% of detected DU145 cells were positive for TaqMan fluorescence.
The inclusion of the protease resulted in a dramatically improved SRY locus detection rate of 97.9%.
We next sought to determine if the two-step workflow was also required for single-cell barcoding of amplicons targeting 8 genomic loci located in TP53, DNMT3A, IDH1, IDH2, FLT3 and NPM1. To do this we synthesized hydrogel beads with oligonucleotides containing both cell identifying barcodes and different gene specific primer sequences 5 . These barcoded beads were microfluidically combined with droplets containing cell lysate generated with or without the protease reagent (Fig 1b) . Prior to PCR amplification, the oligonucleotides are photo-released from the hydrogel supports with UV exposure. Consistent with our earlier single-cell TaqMan reaction observations, amplification of the targeted genomic loci was substantially improved by use of a protease during cell lysis. Although similar numbers of input cells were used for both conditions, the use of protease enabled greater sequencing library DNA yields as assessed by a Bioanalyzer (Fig. 1d) .
Moreover, following sequencing, the average read coverage depth for the 8 targets from each cell was considerably higher when protease was used in the workflow (Fig. 1e ). This data demonstrates the advantage of the two-step workflow for efficient amplification across different genomic loci for targeted single-cell genomic sequencing with molecular barcodes.
Having developed the core capability to perform targeted single-cell DNA sequencing, we next sought to apply the technology to the study of clonal heterogeneity in the context of normal karyotype AML. To provide variant allele information at clinically meaningful loci, we developed a 62 amplicon targeted panel that covers many of the 23 most commonly mutated genes associated with AML progression (Supplementary Table 1 Total workflow time for each sample was less than two days. MiSeq runs generating 250 bp paired-end reads were performed for each of the three samples that were barcoded. On average, 74.7% of the reads (MAPQ > 30) were associated with a cell barcode and correctly mapped to one of the 62-targeted loci (Fig. 2a) . Performance of the panel across the targeted loci is shown in Supplementary Figure 2 .
The Raji cell spike in detection rate across the three sample runs averaged 2.4% and the average allele dropout rate, calculated from two separate heterozygous TP53 SNVs present in the Raji cells, was 5.5% (Fig. 2a) . The allele dropout rate represents the percentage of cells within a run, averaged across the two loci, where the known heterozygous SNV was incorrectly genotyped as either homozygous wild type or homozygous mutant.
Using standard genotype calling algorithms (Online Methods), we identified a total of 17 variant alleles for this patient (Supplementary Table 2 (Fig. 2e) . Interestingly, the single-cell sequencing data does not support this model as only a relatively small DNMT3A single mutant population is observed and this population is at a frequency that can be explained by allele dropout. In contrast, our results suggest that the SNV in TP53 could be the founding mutation since the size of the TP53 (H47R) single mutant clone is larger than what would be expected from allele dropout. Our single-cell approach also unambiguously identified the TP53, DNMT3A and FLT3/ITD triple mutant population as the most abundant neoplastic cell type in the diagnosis and relapse samples (Fig. 2d) .
Moreover, the identification of this clone strongly supports a model where the mutations were serially acquired during the progression of the disease.
Our method enables rapid and cost-effective targeted genomic sequencing of thousands of AML cells in parallel -something that is not feasible with existing technologies. Applying this approach to the study of larger AML patient populations will likely lead to correlations between clonal heterogeneity and clinical outcomes. Although we focused on AML in this study, our method should be applicable to other cancer cell types and profiling of solid tumors that have been dissociated into single-cell suspensions. This capability is poised to complement an increased scientific appreciation of the role that genetic heterogeneity plays in the progression of many cancers as well as a desire by clinicians to make personalized medicine a widespread reality.
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ONLINE METHODS

Cell and patient samples
Raji B-lymphocyte cells were cultured in complete media (RPMI 1640 with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 µg/ml streptomycin) at 37°C with 5% CO 2 . Cells were pelleted at 400 g for 4 min and washed once with HBSS and resuspended in PBS that was density matched with OptiPrep (Sigma-Aldrich) prior to encapsulation in microfluidic droplets.
The clinical AML samples were obtained from a 66 year old man was diagnosed with AML, Frozen bone marrow aspirates were thawed at the time of cell encapsulation and resuspended in 5 ml of FBS on ice, followed by a single wash with PBS. All cell samples were quantified prior to encapsulation by combining 5 µl aliquots of cell suspension with an equal amount of trypan blue (ThermoFisher), then loaded on chamber slides and counted with the Countess Automated Cell
Counter (ThermoFisher). The Raji cells were added to the bone marrow cell samples to achieve a ~1%
final spike-in concentration.
Fabrication and operation of microfluidic devices
We performed the microfluidic droplet handling on devices made from polydimethylsiloxane (PDMS) molds bonded to glass slides; the device channels were treated with Aquapel to make them hydrophobic. The PDMS molds were formed from silicon wafer masters with photolithographically patterned SU-8 (Microchem) on them. We operated the devices primarily with syringe pumps (NewEra), which drove cell suspensions, reagents and fluorinated oils (Novec 7500 and FC-40) with 2-5% PEG-PFPE block-copolymer surfactant into the devices through polyethylene tubing 1 . Merger of the cell lysate containing droplets with the PCR reagent/barcode bead droplets was performed using a microfluidic electrode.
Generation of barcode containing beads
Barcoded hydrogel beads were made as previously reported in Klein et al 2 . Briefly, a monomeric acrylamide solution and an acrydite-modified oligonucleotide were emulsified on a dropmaker with oil containing TEMED. The TEMED initiates polymerization of the acrylamide resulting in highly uniform beads. The incorporated oligonucleotide was then used as a base on which different split-and-pool generated combinations of barcodes were sequentially added with isothermal extension. Targeted gene-specific primers were phosphorylated and ligated to the 5' end of the hydrogel attached oligonucleotides. ExoI was used to digest non-ligated barcode oligonucleotides that could otherwise interfere with the PCR reactions. Because the acrydite oligo also has a photocleavable linker (required for droplet PCR), barcoded oligonucleotide generation could be measured. We were able to convert approximately 45% of the base acrydite oligonucleotide into full-length barcode with gene specific primers attached. Single bead sequencing of beads from individual bead lots was also performed to verify quality of this reagent.
Cell encapsulation and droplet PCR
Following density matching, cell suspensions were loaded into 1 ml syringes and co-flowed with an equal volume of lysis buffer (100 mM Tris pH 8.0, 0.5% IGEPAL, proteinase K 1.0 mg/ml) to prevent premature lysing of cells 3 . The resultant emulsions were then incubated at 37°C for [16] [17] [18] [19] [20] hours prior to heat inactivation of the protease.
Droplet PCR reactions consisted of 1X Platinum Multiplex PCR Master Mix (ThermoFisher), supplemented with 0.2 mg/ml RNAse A. Prior to thermocycling, the PCR emulsions containing the barcode carrying hydrogel beads were exposed to UV light for 8 min to release the oligonucleotides.
Droplet PCR reactions were thermocycled with the following conditions: 95°C for 10 min, 25 cycles of 95°C for 30 s, 72°C for 10 s, 60°C for 4 min, 72°C for 30 s and a final step of 72°C for 2 min. Singlecell TaqMan reactions targeting the SRY locus were performed as previously described 4 .
DNA recovery and sequencing library preparation
Following thermocycling, emulsions were broken using perfluoro-1-octanol and the aqueous fraction was diluted in water. The aqueous fraction was then collected and centrifuged prior to DNA purification using 0.63X of SPRI beads (Beckman Coulter). Sample indexes and Illumina adaptor sequences were then added via a 10 cycle PCR reaction with 1X Phusion High-Fidelity PCR Master Mix. A second 0.63X SPRI purification was then performed on the completed PCR reactions and samples were eluted in 10 µl of water. Libraries were analyzed on a DNA 1000 assay chip with a Bioanalyzer (Agilent Technologies), and sequenced on an Illumina MiSeq with either 150 bp or 250 bp paired end multiplexed runs. A single sequencing run was performed for each barcoded single-cell library prepared with our microfluidic workflow. A 5% ratio of PhiX DNA was used in the sequencing runs.
Analysis of next generation sequencing data
Sequenced reads were trimmed for adapter sequences (cutadapt 5, 6 ), and aligned to the hg19 human genome using bwa-mem 7, 8 after extracting barcode information. After mapping, on target sequences were selected using standard bioinformatics tools (samtools 9 ), and barcode sequences were GATK 3.7 11 was used to genotype the diagnosis sample with a joint-calling approach.
Mutations with a quality score higher than 8,000 were considered accurate variants. The presence of these variants as well as the potential FLT3/ITD were called at a single cell level across the three samples using Freebayes 12 . TP53, ASXL1, FLT3 and DNMT3A genotype cluster analysis was performed using heatmap3 for R 13 . The non-patient Raji cell spike in populations were removed for this analysis.
Bulk sequencing using capture targeted sequencing
We designed a SureSelect custom panel of 295 genes (Agilent Technologies, Santa Clara, CA)
that are recurrently mutated in hematologic malignancies (Supplementary Table 3 ). Extracted genomic DNA from bone marrow aspirates was fragmented and bait-captured according to manufacturer protocols. Captured DNA libraries were then sequenced using a HiSeq 2000 sequencer (Illumina, San
